DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 20151/S-031/S-055/S-058/S-060

SUPPLEMENT APPROVAL

Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Attention: James H. Medley, PhD
Regulatory Strategist, contract
445 Eastern Point Road
Groton, CT 06340

Dear Dr. Medley:

Please refer to your Supplemental New Drug Applications (sNDA) dated February 9, 2004 (NDA 20151/S-031), May 14, 2009 (20151/S-055), December 7, 2011 (20151/S-058), and May 1, 2012 (20151/S-060) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Effexor (venlafaxine hydrochloride) 25 mg, 37.5 mg, 50 mg, 75 mg, and 100 mg Tablets.

We acknowledge receipt of your amendments dated:
- 20151/S-031: May 23, 2008, June 18, 2008, and August 8, 2012
- 20151/S-055: February 28, 2011

The June 18, 2008, and February 28, 2011, submissions constituted a complete response to our May 15, 2008 (20151/S-031), and December 20, 2010 (20151/S-055), action letters.

These supplemental new drug applications provide for the following changes to product labeling:

20151/S-031 submitted as "Prior Approval"
- Revisions to the **PRECAUTIONS-Carcinogenesis, Mutagenesis, Impairment of Fertility-** *Impairment of Fertility* subsection to be consistent with Pristiq (desvenlafaxine succinate) labeling.

20151/S-055 submitted as "Prior Approval"
- Provides for a comprehensive Medication Guide as requested in an Agency supplement request letter dated April 16, 2009.

20151/S-058 submitted as "Changes Being Effected"
- Provides for the addition of methylene blue to the Warnings section

20151/S-060 submitted as "Prior Approval"
- Provides for class labeling revisions to the **Contraindications**, **Warnings**, **Dosage And Administration**, & **Medication Guide** regarding serotonin toxicity associated with the co-

administration of linezolid and methylene blue as requested in an Agency supplement request letter dated March 5, 2012.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions agreed upon in an email communication dated December 6, 2012, between you and Paul David, of this Agency.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact CDR Kofi Ansah, Pharm.D., Senior Regulatory Project Manager, at (301)796-4158 or email: Kofi.Ansah@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
CAPT USPHS
Director (acting)
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
12/12/2012